 |
|
Biochemoprevention for Dysplastic Lesions of the Upper Aerodigestive Tract
Vali A. Papadimitrakopoulou, MD;
Gary L. Clayman, MD;
Dong M. Shin, MD;
Jeffrey N. Myers, MD;
Ann M. Gillenwater, MD;
Helmuth Goepfert, MD;
Adel K. El-Naggar, MD;
Jan S. Lewin, PhD;
Scott M. Lippman, MD;
Waun K. Hong, MD
Arch Otolaryngol Head Neck Surg. 1999;125:1083-1089.
Objectives To evaluate the efficacy and secondarily the toxic effects of biochemopreventive therapy (high-dose isotretinoin [13-cis-retinoic acid],  -tocopherol, and interferon alfa) in the reversal of advanced premalignant lesions of the upper aerodigestive tract and to correlate the therapeutic events with modulation of biomarkers.
Design Prospective, nonrandomized chemoprevention trial.
Setting Tertiary cancer care referral center and ambulatory care.
Participants Thirty-six patients with advanced premalignant lesions of the upper aerodigestive tract, without cancer during the 2 years before the intervention, with evaluable lesions, and without retinoid therapy for 3 months before the trial.
Intervention Administration of oral isotretinoin (100 mg/m2 per day), oral -tocopherol (1200 IU/d), and subcutaneous interferon alfa (3 megaunits per square meter twice weekly) for 12 months, with serial biopsies and clinical examination at 0, 6, 12, and 18 months from study start.
Main Outcome Measures Clinical and histologic responses to the intervention.
Results Of the 36 patients, evaluation was possible in 30 for response at 6 months and in 21 at 12 months. At 6 months, there were 10 pathologic complete responses and 7 partial responses; at 12 months, 7 complete and 3 partial responses. A striking difference in response was observed in favor of laryngeal lesions (9/19 [47%] complete response rate at 6 months and 7/14 [50%] at 12 months vs 1/11 [9%] and 0/7 [0%], respectively, for oral lesions). Toxic effects were acceptable and did not exceed grade 3.
Conclusion Biochemoprevention is a promising biologic approach for laryngeal dysplasia and needs to be investigated further.
From the Departments of Thoracic–Head and Neck Medical Oncology (Drs Papadimitrakopoulou, Shin, and Hong), Head and Neck Surgery (Drs Clayman, Myers, Gillenwater, Goepfert, and Lewin), Pathology (Dr El-Naggar), and Clinical Cancer Prevention (Dr Lippman), University of Texas, M. D. Anderson Cancer Center, Houston.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Role of Cyclooxygenase-2 in Tumor Progression and Survival of Head and Neck Squamous Cell Carcinoma
Cancer Prevention Research 2009;2:823-829.
American Society of Clinical Oncology Policy Statement: The Role of the Oncologist in Cancer Prevention and Risk Assessment
Zon et al.
JCO 2009;27:986-993.
ABSTRACT
| FULL TEXT
Cyclin D1 and Cancer Development in Laryngeal Premalignancy Patients
Papadimitrakopoulou et al.
Cancer Prevention Research 2009;2:14-21.
ABSTRACT
| FULL TEXT
High-Dose Fenretinide in Oral Leukoplakia
William et al.
Cancer Prevention Research 2009;2:22-26.
ABSTRACT
| FULL TEXT
Chromosomal Deletions and Progression of Premalignant Lesions: Less Is More
Wistuba and Meyerson
Cancer Prevention Research 2008;1:404-408.
FULL TEXT
Topical Application of a Bioadhesive Black Raspberry Gel Modulates Gene Expression and Reduces Cyclooxygenase 2 Protein in Human Premalignant Oral Lesions
Mallery et al.
Cancer Res. 2008;68:4945-4957.
ABSTRACT
| FULL TEXT
Effects of a Topically Applied Bioadhesive Berry Gel on Loss of Heterozygosity Indices in Premalignant Oral Lesions
Shumway et al.
Clin. Cancer Res. 2008;14:2421-2430.
ABSTRACT
| FULL TEXT
Identification of High-risk Cohorts for Head and Neck Cancer Prevention Based on Tissue Markers LOH and cyclin D1
William and Papadimitrakopoulou
Am Soc Clin Oncol Ed Book 2008;2008:66-68.
ABSTRACT
| FULL TEXT
Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer
Choe et al.
Molecular Cancer Therapeutics 2005;4:1448-1455.
ABSTRACT
| FULL TEXT
Phase 2 Bioadjuvant Study of Interferon Alfa-2a, Isotretinoin, and Vitamin E in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up
Seixas-Silva et al.
Arch Otolaryngol Head Neck Surg 2005;131:304-307.
ABSTRACT
| FULL TEXT
Head and Neck Cancer: Meeting Summary and Research Opportunities
Grandis et al.
Cancer Res. 2004;64:8126-8129.
ABSTRACT
| FULL TEXT
Novel Management of Oral Cancer: A Paradigm of Predictive Oncology
Sudbo
Clin Med Res 2004;2:233-242.
ABSTRACT
| FULL TEXT
Simultaneously Targeting Epidermal Growth Factor Receptor Tyrosine Kinase and Cyclooxygenase-2, an Efficient Approach to Inhibition of Squamous Cell Carcinoma of the Head and Neck
Chen et al.
Clin. Cancer Res. 2004;10:5930-5939.
ABSTRACT
| FULL TEXT
Advances in Chemoprevention of Head and Neck Cancer
Rhee et al.
The Oncologist 2004;9:302-311.
ABSTRACT
| FULL TEXT
Chemoprevention of Cancer
Tsao et al.
CA Cancer J Clin 2004;54:150-180.
ABSTRACT
| FULL TEXT
The Use of Genetic Markers in the Clinical Care of Patients With Head and Neck Cancer
Friedlander
Arch Otolaryngol Head Neck Surg 2003;129:363-366.
FULL TEXT
Cyclin D1 Genotype, Response to Biochemoprevention, and Progression Rate to Upper Aerodigestive Tract Cancer
Izzo et al.
JNCI J Natl Cancer Inst 2003;95:198-205.
ABSTRACT
| FULL TEXT
Biologic Correlates of a Biochemoprevention Trial in Advanced Upper Aerodigestive Tract Premalignant Lesions
Papadimitrakopoulou et al.
Cancer Epidemiol. Biomarkers Prev. 2002;11:1605-1610.
ABSTRACT
| FULL TEXT
Cancer Chemoprevention in the 21st Century: Genetics, Risk Modeling, and Molecular Targets
Hong et al.
JCO 2000;18:9s-18.
FULL TEXT
Biochemopreventive Therapy for Patients With Premalignant Lesions of the Head and Neck and p53 Gene Expression
Shin et al.
JNCI J Natl Cancer Inst 2000;92:69-73.
FULL TEXT
|
